Samantha Singer is an accomplished biotechnology leader and brings to Abata more than two decades of expertise in company creation, corporate development and operations.

She is currently president and chief executive officer at Abata Therapeutics, a biotech launched in 2021 to develop transformational Treg cell therapies for serious autoimmune disease. Previously, she was an entrepreneur-in-residence at Third Rock Ventures, where she focused on company creation across the firm’s portfolio, including interim chief operating officer roles for Thrive Earlier Detection (acquired by Exact Sciences) and Celsius Therapeutics. Prior to joining Third Rock, Samantha was the chief operating officer of the Broad Institute, where she oversaw the institute’s finance, business development, alliance management, facilities, information technology, human resources and legal teams. Previously, she served as vice president for corporate strategy and chief of staff for the CEO at Biogen. At Biogen, she also held leadership roles in organization effectiveness and global supply chain. Before Biogen, Samantha was a strategy consultant at the Boston Consulting Group and as an independent consultant focused on biotech companies and biomedical academic centers.

Samantha is a member of the board of directors of the Institute for Protein Innovation. She previously served on the board of directors of Rodin Therapeutics (acquired by Alkermes) and the 5:01 Special Acquisition Corp.